Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
-
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
-
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
-
FRACTYL HEALTH PRESENTS CLINICAL UPDATE ON REVITA® GERMAN REAL- WORLD REGISTRY FOR PATIENTS WITH ADVANCED TYPE 2 DIABETES (T2D)
-
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
-
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
-
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
-
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation
-
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs